Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

coagulation factor X

Alternative Names: coagulation factor X
Clinical Status: Inactive
Latest Update: 2025-05-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: N/A

Novel Mechanism: No

Modality: N/A

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: Austria | Belgium | Brazil | Chile | Croatia | Czech | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Malaysia | Malta | Norway | Poland | Portugal | Slovakia | Slovenia | Sweden | Turkey | United Arab Emirates | United States

Approved Indications: None

Known Adverse Events: None

Company: Bio Products Laboratory
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for coagulation factor X

Countries in Clinic: Austria, Croatia, Germany, Italy, Poland, Spain

Active Clinical Trial Count: 1

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Injuries/wounds Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated
LEX-210

P3

Recruiting

Injuries/wounds Unspecified

2026-04-05

2025-05-02

Treatments

Recent News Events

Date

Type

Title

12/05/2023

News Article

 GC Biopharma USA Announces Publication Describing Proprietary Cation Exchange Chromatography (CEX) Removing FXIa from a 10% Intravenous Immunoglobulin (GC5107) Preparation

12/06/2022

News Article

 Aronora Announces Clinical Data to Be Presented at the 64th American Society of Hematology Annual Meeting

12/06/2022

News Article

 Aronora Announces Clinical Data to Be Presented at the 64th American Society of Hematology Annual Meeting

12/02/2020

News Article

 Aronora Announces Clinical Data to Be Presented at the 62nd American Society of Hematology Annual Meeting

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions